Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Nurix Therapeutics (NRIX) Accumulated Expenses: 2019-2025

Historic Accumulated Expenses for Nurix Therapeutics (NRIX) over the last 5 years, with Aug 2025 value amounting to $44.0 million.

  • Nurix Therapeutics' Accumulated Expenses rose 57.96% to $44.0 million in Q3 2025 from the same period last year, while for Aug 2025 it was $44.0 million, marking a year-over-year increase of 57.96%. This contributed to the annual value of $38.0 million for FY2024, which is 52.16% up from last year.
  • Latest data reveals that Nurix Therapeutics reported Accumulated Expenses of $44.0 million as of Q3 2025, which was up 18.79% from $37.0 million recorded in Q2 2025.
  • Nurix Therapeutics' Accumulated Expenses' 5-year high stood at $44.4 million during Q1 2025, with a 5-year trough of $7.7 million in Q2 2021.
  • For the 3-year period, Nurix Therapeutics' Accumulated Expenses averaged around $29.4 million, with its median value being $27.8 million (2024).
  • In the last 5 years, Nurix Therapeutics' Accumulated Expenses skyrocketed by 157.02% in 2022 and then dropped by 8.33% in 2023.
  • Quarterly analysis of 5 years shows Nurix Therapeutics' Accumulated Expenses stood at $14.5 million in 2021, then spiked by 54.15% to $22.4 million in 2022, then increased by 11.33% to $25.0 million in 2023, then spiked by 52.16% to $38.0 million in 2024, then spiked by 57.96% to $44.0 million in 2025.
  • Its last three reported values are $44.0 million in Q3 2025, $37.0 million for Q2 2025, and $44.4 million during Q1 2025.